Anixa Biosciences, Inc. (NASDAQ:ANIX) Director Buys $14,100.00 in Stock

Anixa Biosciences, Inc. (NASDAQ:ANIX) Director Arnold M. Baskies bought 5,000 shares of Anixa Biosciences stock in a transaction dated Tuesday, January 28th. The shares were purchased at an average cost of $2.82 per share, for a total transaction of $14,100.00. Following the completion of the transaction, the director now owns 120,000 shares of the company’s stock, valued at approximately $338,400. This represents a 4.35 % increase in their position. The purchase was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.

Anixa Biosciences Stock Performance

Shares of ANIX stock traded up $0.11 on Wednesday, reaching $2.91. 48,730 shares of the company’s stock traded hands, compared to its average volume of 128,639. The company has a market capitalization of $93.70 million, a P/E ratio of -7.47 and a beta of 0.90. The business’s 50 day moving average price is $2.75 and its two-hundred day moving average price is $3.05. Anixa Biosciences, Inc. has a 12-month low of $2.07 and a 12-month high of $4.70.

Anixa Biosciences (NASDAQ:ANIX) last released its quarterly earnings data on Friday, January 10th. The company reported ($0.09) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.11) by $0.02. Research analysts predict that Anixa Biosciences, Inc. will post -0.46 earnings per share for the current year.

Wall Street Analysts Forecast Growth

ANIX has been the subject of several recent analyst reports. D. Boral Capital reissued a “buy” rating and set a $10.00 price objective on shares of Anixa Biosciences in a report on Wednesday, January 22nd. HC Wainwright reissued a “buy” rating and issued a $7.00 price objective on shares of Anixa Biosciences in a research note on Tuesday, November 19th.

Hedge Funds Weigh In On Anixa Biosciences

A number of institutional investors have recently made changes to their positions in the business. Tyler Stone Wealth Management increased its stake in Anixa Biosciences by 100.0% during the third quarter. Tyler Stone Wealth Management now owns 42,016 shares of the company’s stock valued at $132,000 after acquiring an additional 21,008 shares during the period. International Assets Investment Management LLC lifted its stake in shares of Anixa Biosciences by 170.0% during the third quarter. International Assets Investment Management LLC now owns 37,800 shares of the company’s stock valued at $1,190,000 after acquiring an additional 23,800 shares during the period. Westside Investment Management Inc. lifted its stake in Anixa Biosciences by 151.8% in the third quarter. Westside Investment Management Inc. now owns 35,000 shares of the company’s stock valued at $110,000 after buying an additional 21,100 shares during the period. Finally, Virtu Financial LLC bought a new position in Anixa Biosciences during the third quarter worth about $34,000. 29.13% of the stock is currently owned by institutional investors.

About Anixa Biosciences

Anixa Biosciences, Inc, a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. The company's therapeutics programs include the development of a chimeric endocrine receptor T-cell therapy, a novel form of chimeric antigen receptor T-cell (CAR-T) technology focusing on the treatment of ovarian cancer.